Asia-Pacific Acute Myeloid Leukemia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

The market is segmented by Therapy (Chemotherapy, Targeted Therapy, Stem Cell Transplant, Other Therapies), and Geography

Market Snapshot

Fruits and Veget

Study Period:


Base Year:


Major Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

There has been an increasing trend in the AML cases seen in the Asian region that has increased the number of clinical trials into new therapies for leukemia patients. In Japan, approximately 4,500 patients were diagnosed with AML every year, according to a 2018 report by Astellas Pharma Inc. Moreover, the survey has also reported that the prevalence of AML is higher in the geriatric population. As the geriatric population is increasing in percentage, this disease may cause an economic burden on the overall population.

According to a report by Elton B. Stephens Co.(EBSCO), 2017, the prevalence (5-year period) of AML in lower-income Asia-Pacific countries and high-income Asia- Pacific countries was 4 per 100,000 and 7 per 100,000, respectively. Asia-pacific comprises of countries that are not only economically developing, but their population is also increasing every year at a significant rate. Hence as the population of these countries increase, the risk of incidence of AML is also high.

Owing to the increase in the prevalence of AML in the Asia-Pacific region, this market is expected to grow during the forecast period.

Scope of the Report

Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells, which get collected in the bone marrow and disturb the production of normal blood cells.

By Therapy
Anthracycline Drugs
Alkylating Agents
Other Chemotherapies
Targeted Therapy
Stem Cell Transplant
Other Therapies
Asia Pacific
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

Key Market Trends

Daunorubicin to Witness Highest CAGR in Anthracycline Drugs Segment

Daunorubicin is a chemotherapy drug used to treat a certain type of acute myeloid leukemia (AML; a type of cancer of the white blood cells). It is also used with other drugs to treat various types of acute lymphocytic leukemia. Daunorubicin is a class of medication known as anthracyclines and it works by stopping the growth of cancer cells in the body.

The medication is given only by injection into the vein and must not be given by injection into a muscle or under the skin and if the drug by any chance gets leaks into the skin/muscle it may cause severe damage. In the young adults suffering from AML, the intensifying induction therapy with a high dose of daunorubicin has seen improving the rate of complete remission and the duration of overall survival, as compared with the standard dosage.

Daunorubicin has found to be the most effective and safe medicines needed in a health care system and has become the choice for acute myeloid leukemia (AML) along with Cytarabine for the past 4 decades. It slows or stops the growth of cancer cells in the body. Therefore, it is believed that Daunorubicin will witness the highest CAGR over the forecast period.

Fruits and Veget

To understand key trends, Download Sample Report

Competitive Landscape

The market for acute myeloid leukemia treatment in Asia-Pacific is moderately competitive and comprises of the global players majorly. Some of the key players in this market are Novartis AG, Pfizer Inc., Teva Pharmaceuticals, AbbVie Inc., among others. With the rising focus of pharmaceutical companies to provide better therapeutics for cancer, it is believed that more companies will be penetrating the market in the near future.

Table Of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia

      2. 4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Complications Related to Chemotherapy

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Therapy

      1. 5.1.1 Chemotherapy

        1. Anthracycline Drugs

          1. Daunomycin

          2. Idarubicin

          3. Mitoxantrone

        2. Alkylating Agents

        3. Anti-metabolites

        4. Other Chemotherapies

      2. 5.1.2 Targeted Therapy

      3. 5.1.3 Stem Cell Transplant

      4. 5.1.4 Other Therapies

    2. 5.2 Geography

      1. 5.2.1 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific


    1. 6.1 Company Profiles

      1. 6.1.1 Astellas Pharma Inc.

      2. 6.1.2 AbbVie Inc.

      3. 6.1.3 Celgene Corporation

      4. 6.1.4 Daiichi Sankyo Company Limited

      5. 6.1.5 Novartis AG

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Teva Pharmaceutical Industries Ltd

      8. 6.1.8 Mylan NV

      9. 6.1.9 Sun Pharmaceutical Industries Ltd

      10. 6.1.10 Fresenius SE & Co. KGaA


* List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

Related Reports